

Xavier Mulet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11112051/publications.pdf>

Version: 2024-02-01

28
papers

1,720
citations

471509

17
h-index

501196

28
g-index

28
all docs

28
docs citations

28
times ranked

2018
citing authors

#	ARTICLE	IF	CITATIONS
1	The increasing threat of <i>Pseudomonas aeruginosa</i> high-risk clones. <i>Drug Resistance Updates</i> , 2015, 21-22, 41-59.	14.4	475
2	<i>Pseudomonas aeruginosa</i> Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3091-3099.	3.2	197
3	Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 658-663.	3.0	157
4	<i>Pseudomonas aeruginosa</i> carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2022-2027.	3.0	132
5	Biological Markers of <i>Pseudomonas aeruginosa</i> Epidemic High-Risk Clones. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5527-5535.	3.2	104
6	Azithromycin in <i>Pseudomonas aeruginosa</i> Biofilms: Bactericidal Activity and Selection of <i>nfxB</i> Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1552-1560.	3.2	73
7	Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in <i>Pseudomonas aeruginosa</i> Cystic Fibrosis Chronic Lung Infection. <i>PLoS ONE</i> , 2013, 8, e71001.	2.5	69
8	In Vivo Emergence of Resistance to Novel Cephalosporin- β -Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β -Lactamase (OXA-539) in Sequence Type 235 <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	61
9	Antagonistic Interactions of <i>Pseudomonas aeruginosa</i> Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4560-4568.	3.2	58
10	The <i>Pseudomonas aeruginosa</i> CreBC Two-Component System Plays a Major Role in the Response to β -Lactams, Fitness, Biofilm Growth, and Global Regulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5084-5095.	3.2	56
11	Ceftolozane/tazobactam for the treatment of multidrug resistant <i>Pseudomonas aeruginosa</i> : experience from the Balearic Islands. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2191-2200.	2.9	53
12	Molecular Epidemiology and Multidrug Resistance Mechanisms of <i>Pseudomonas aeruginosa</i> Isolates from Bulgarian Hospitals. <i>Microbial Drug Resistance</i> , 2013, 19, 355-361.	2.0	45
13	Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the <i>Caenorhabditis elegans</i> <i>Pseudomonas aeruginosa</i> Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	39
14	Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of <i>Pseudomonas aeruginosa</i> strain PAO1. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1399-1404.	3.0	37
15	Activity of ceftolozane/tazobactam against <i>Pseudomonas aeruginosa</i> and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 682-688.	2.5	37
16	Emergence of Resistance to Novel Cephalosporin- β -Lactamase Inhibitor Combinations through the Modification of the <i>Pseudomonas aeruginosa</i> MexCD-OprJ Efflux Pump. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0008921.	3.2	29
17	Overexpression of MexCD-OprJ Reduces <i>Pseudomonas aeruginosa</i> Virulence by Increasing Its Susceptibility to Complement-Mediated Killing. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2426-2429.	3.2	23
18	O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 541-544.	2.9	17

#	ARTICLE	IF	CITATIONS
19	<i>In Vivo</i> Evolution of GES β -Lactamases Driven by Ceftazidime/Avibactam Treatment of <i>Pseudomonas aeruginosa</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0098621.	3.2	14
20	Characterization of AmpC β -lactamase mutations of extensively drug-resistant <i>Pseudomonas aeruginosa</i> isolates that develop resistance to ceftolozane/tazobactam during therapy. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 474-478.	0.5	13
21	Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired β -Lactamases on <i>Pseudomonas aeruginosa</i> Virulence. <i>Microbiology Spectrum</i> , 2022, 10, e0201921.	3.0	8
22	WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa084.	2.1	7
23	Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of <i>Pseudomonas aeruginosa</i> in clinical isolates belonging to a Spanish nationwide multicenter study. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 279-282.	0.5	4
24	Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacterales: The Future of Networking Data Analysis With Online Software. <i>Frontiers in Microbiology</i> , 2021, 12, 789731.	3.5	4
25	VIM-47, a New Variant of the Autochthonous Metallo- β -Lactamase VIM-13 from the Balearic Islands in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3251-3252.	3.2	3
26	Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of <i>Pseudomonas aeruginosa</i> in clinical isolates belonging to a Spanish nationwide multicenter study. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021, 39, 279-282.	0.3	2
27	Whole-genome sequence-guided PCR for the rapid identification of the <i>Pseudomonas aeruginosa</i> ST175 high-risk clone directly from clinical samples. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 945-949.	3.0	2
28	Characterization of AmpC β -lactamase mutations of extensively drug-resistant <i>Pseudomonas aeruginosa</i> isolates that develop resistance to ceftolozane/tazobactam during therapy. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 474-478.	0.3	1